iBio, Inc. (NYSE:IBIO)
Industry: Major Pharmaceuticals

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.

Current Quote*
Last: $0.863
Change: 0.001
Book: $1.421
Volume: 7,275

As Of: 03/20 13:36 ET
*Quotes delayed by 20min.

Graphs for IBIO


3 Month Graph


6 Month Graph


1 Year Graph